Amgen Inc. Debt Securities, Available-for-sale, Amortized Cost
Amgen Inc. (AMGN) had Debt Securities, Available-for-sale, Amortized Cost of $13.41 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $13.41B.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $11.48B.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $8.53B.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $8.71B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $13.41B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $11.48B 10-Q · filed 2026-05-01 |
| 2025-12-31 | $8.53B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $8.71B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $7.49B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $8.30B 10-Q · filed 2025-05-02 |
| 2024-12-31 | $11.49B 10-K · filed 2026-02-13 |
| 2024-09-30 | $8.58B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $8.81B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $9.24B 10-Q · filed 2024-05-03 |
| 2023-12-31 | $10.40B 10-K · filed 2025-02-14 |
| 2023-09-30 | $34.21B 10-Q · filed 2023-10-31 |
| 2023-06-30 | $33.62B 10-Q · filed 2023-08-04 |
| 2023-03-31 | $31.07B 10-Q · filed 2023-04-28 |
| 2022-12-31 | $4.33B 10-K · filed 2024-02-14 |
| 2022-09-30 | $10.92B 10-Q · filed 2022-11-04 |
| 2022-06-30 | $6.41B 10-Q · filed 2022-08-05 |
| 2022-03-31 | $5.85B 10-Q · filed 2022-04-28 |
| 2021-12-31 | $7.30B 10-K · filed 2023-02-09 |
| 2021-09-30 | $12.28B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $7.16B 10-Q · filed 2021-08-04 |
| 2021-03-31 | $9.72B 10-Q · filed 2021-04-28 |
| 2020-12-31 | $9.84B 10-K · filed 2022-02-16 |
| 2020-09-30 | $11.59B 10-Q · filed 2020-10-29 |
| 2020-06-30 | $10.73B 10-Q · filed 2020-07-29 |
| 2020-03-31 | $7.29B 10-Q · filed 2020-05-01 |
| 2019-12-31 | $8.21B 10-K · filed 2021-02-09 |
| 2019-09-30 | $20.14B 10-Q · filed 2019-10-30 |
| 2019-06-30 | $21.07B 10-Q · filed 2019-07-31 |
| 2019-03-31 | $25.77B 10-Q · filed 2019-05-01 |
| 2018-12-31 | $29.06B 10-K · filed 2020-02-12 |
| 2018-09-30 | $29.81B 10-Q · filed 2018-10-31 |
| 2018-06-30 | $29.32B 10-Q · filed 2018-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |